CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
由大颗粒淋巴细胞驱动且对类固醇有反应的 CAR-T 细胞治疗后重度血细胞减少
英文原题：Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids.
查看英文原题
Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫效应细胞相关血液毒性（ICAHT）是嵌合抗原受体（CAR）T 细胞治疗常见毒性，并可造成显著患病负担。严重 ICAHT 的发生似乎涉及多种因素，因此管理困难。本文报告 3 例弥漫大 B 细胞淋巴瘤患者接受 axicabtagene ciloleucel（axi-cel）后发生严重 ICAHT 的病例；患者骨髓中出现大颗粒淋巴细胞扩增，免疫表型为 CD3/CD57 阳性、非 CAR-T 细胞。我们显示，低剂量类固醇可用于治疗这些患者，并显著缓解血细胞减少，且未对基础恶性肿瘤产生不利影响。
展开英文摘要原文
Immune effector cell-associated hematotoxicity (ICAHT) is a common toxicity associated with an important morbidity after chimeric antigen receptor (CAR)-T-cell therapy. Multiple factors seem to be involved in the development of severe ICAHT, making its management difficult.
Here, we report three cases of severe ICAHT after axicabtagene-ciloleucel (axi-cel) for diffuse large B-cell lymphoma showing an expansion of large granular lymphocyte in the bone marrow with a CD3/CD57-positive non-CAR-T immunophenotype.
We show that it is possible to treat them with low-dose steroids, obtaining a striking resolution of cytopenias with no deleterious impact on the underlying malignancy.
论文信息
- 作者
- Capes A、Morin A、Banet A、Suner L、Ricard L、Corre E、Brissot E、Stocker N
- 单位
- Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Paris, France.France
- 文献类型
- 病例报告
- 期刊
- British journal of haematology2025 Jan
- 原文标识
- PubMed 39425562 · DOI 10.1111/bjh.19822
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →